The overexpression of CD147 in cancer is able to further potentiate VEGFR-2 activation, suggesting that a combinatory therapy of an antiangiogenic drug together with an inhibitor of CD147/VEGFR-2 interaction may have a greater impact on inhibiting angiogenesis and malignancy [87]. Here, BSG is linked to cancer.